SAN DIEGO, Feb. 23, 2024 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor today announced that the European Medicines Agency’s (EMA) CHMP has recommended approval of sparsentan for the treatment …
Ad hoc announcement pursuant to Art. 53 LR Read full press release here
On December 20, 2023, TARPEYO received full FDA approval for the new indication to reduce the loss of kidney function in adults with IgA Nephropathy (IgAN) who are at risk …
We want to tell you about an important research collaboration between IgA Nephropathy Foundation and the National Kidney Foundation (NKF). This research will have two phases. First, separate surveys of …
The IgA Nephropathy Foundation Launches First-Ever Cookbook Ahead of IgAN Awareness Day The Second Annual ‘IgAN Aware Day’ brings attention to the need for earlier diagnosis and treatments; cookbook offers …
May 25, 2022 – The IgA Nephropathy Foundation (IGAN Foundation), a nonprofit dedicated to supporting patients with a rare autoimmune kidney disease called IgA Nephropathy, today announced its formation of …
There is a lot of technical language around IgAN and it can seem confusing and overwhelming when receiving a diagnosis for yourself or a loved one. You may have many …
The NKF and IGANF conducted an EL-PFDD meeting on IgAN to inform the FDA on the patient perspective on living with this disease. Understanding the patient perspective will help the …
Abstract The randomized, controlled STOP-IgAN trial in patients with IgA nephropathy (IgAN) and substantial proteinuria showed no benefit of immunosuppression added on top of supportive care on renal function over …
Abstract IgA nephropathy (IgAN) is an important cause of ESKD for which there are no approved therapies. A challenge for evaluating treatments for IgAN is the usual long time course …
Stuart Miller, Moderator Patient Panel BIO Stuart is an advocate for NKF and an ambassador for AAKP. He was diagnosed with IgA Nephropathy in May of 2008. Making some lifestyle …
Diagnosis of IgA nephropathy The diagnostic feature of immunoglobulin A (IgA) nephropathy (IgAN) is the substantial accumulation of IgA in the filtering structures (glomeruli) of the kidneys. When IgAN was …
